B3GAT2 as a Radioligand Therapy Target
B3GAT2, beta-1,3-glucuronyltransferase 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, B3GAT2 staining is highest in kidney cancer (100% of samples positive), liver cancer (100% of samples positive) and thyroid cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is B3GAT2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
B3GAT2 expression in cancer
Protein expression of B3GAT2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.78 | High | 100% |
| Liver Cancer | 0.78 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Bladder Cancer | 0.73 | High | 100% |
| Prostate Cancer | 0.73 | High | 100% |
| Pancreatic Cancer | 0.70 | High | 100% |
| Ovarian Cancer | 0.70 | High | 100% |
| Breast Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Gastric Cancer | 0.67 | High | 100% |
| Testicular Cancer | 0.67 | High | 100% |
| Colorectal Cancer | 0.64 | High | 100% |
| Cervical Cancer | 0.64 | High | 100% |
| Skin Cancer | 0.61 | High | 100% |
| Endometrial Cancer | 0.58 | High | 100% |
| Melanoma | 0.58 | High | 100% |
| Lymphoma | 0.50 | Medium | 100% |
| Neuroendocrine Tumors | 0.50 | Medium | 100% |
| Lung Cancer | 0.50 | Medium | 100% |
| Glioma | 0.37 | Medium | 70% |
Is B3GAT2 internalized?
Nuclens has not yet extracted internalization evidence for B3GAT2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
B3GAT2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for B3GAT2 yet. Search ClinicalTrials.gov for B3GAT2 trials.
B3GAT2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See B3GAT2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
B3GAT2 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.08 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how B3GAT2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.